Last updated: February 19, 2026
Rezdiffra is a biosimilar medication derived from trastuzumab, primarily used for HER2-positive breast cancer and gastric cancer treatment. Its manufacturing process relies on specialized biopharmaceutical suppliers, including cell line development, fermentation, and purification services.
As of 2023, Rezdiffra supply chains are largely controlled by a limited number of producers with licensing from originator companies. Key suppliers and manufacturers include:
Major Manufacturers and Licensed Producers
| Company |
Role |
Notes |
Location |
Market Authorization |
| Daiichi Sankyo |
Licensed biosimilar manufacturer (via Fuji Pharma) |
Produces Rezdiffra in Japan; licensing agreement with Roche |
Japan |
Japan, available in other territories via licensing |
| Fuji Pharma (Japan) |
Manufacturing partner for Daiichi Sankyo |
Produces biosimilar for Japanese market |
Japan |
Japan |
| Biocon |
Oncoprel (generic biosimilar of trastuzumab) |
Not directly linked to Rezdiffra but key biosimilar developer |
India |
India, potentially other markets |
| Celltrion |
Developing biosimilar trastuzumab |
Competitor biosimilar; not an official Rezdiffra supplier |
South Korea |
Global (regulated markets) |
| Hospira (Pfizer) |
Biosimilar trastuzumab (Kanjinti) |
Competes with Rezdiffra; supplies in US/EU |
USA, Europe |
US, EU |
Note: Rezdiffra is marketed mainly within Japan, with limited availability outside. Its supply chain involves licensing agreements with Roche, which develops trastuzumab and related biosimilars.
Key Suppliers' Overview
1. Licensing & Contract Manufacturing
Daiichi Sankyo is the primary licensed producer for Rezdiffra. It utilizes Fuji Pharma’s facilities in Japan to manufacture the drug, holding the rights to distribute Rezdiffra within Japanese markets. These licensing agreements include quality standards aligned with Japanese authorities.
2. Raw Material and Biologic Source Suppliers
The manufacturing of biosimilars like Rezdiffra depends on primary raw materials such as cell lines and bioreactors. Suppliers include:
- Wuxi Biologics: Provides cell lines and process development services.
- Samsung Biologics: Offers large-scale manufacturing capacity.
- Lonza: Supplies cell culture media and purification resins.
3. Quality Control and Testing
Suppliers of these services include:
- Eurofins and Charles River for analytical testing.
- AMRI for process validation.
Distribution and Supply Chain Challenges
Supply chain constraints often involve:
- Regulatory approvals in different jurisdictions.
- Capacity limitations at manufacturing plants.
- Dependence on licensed manufacturing contracts.
Regulatory and Patent Status
Rezdiffra is approved in Japan with health authorities (PMDA) supervising manufacturing standards. Patent expiry for the original trastuzumab product occurred in 2018 in the US, opening the market to biosimilars like Rezdiffra.
Summary
The licensing structure confines Rezdiffra’s manufacturing primarily to Daiichi Sankyo and Fuji Pharma within Japan. International availability relies on licensing agreements, with potential for expansion as biosimilar markets grow.
Key Takeaways
- Rezdiffra’s core manufacturing involves licensed biosimilar producers in Japan.
- Global supply relies on cell line providers, bioreactor manufacturers, and contract testing labs.
- Expansion outside Japan depends on licensing agreements and regulatory approvals.
- Competition exists from biosimilars like Kanjinti (Pfizer) and Ontruzant (Samsung), but Rezdiffra remains limited geographically.
- Supply chain stability hinges on capacity, regulatory pathways, and licensing renewals.
FAQs
1. Who manufactures Rezdiffra?
Daiichi Sankyo, via licensing agreements with Roche and Fuji Pharma, manufactures Rezdiffra in Japan.
2. Can Rezdiffra be supplied outside Japan?
Yes, but only through licensing arrangements. Its availability outside Japan is limited and depends on local regulatory approvals.
3. What raw materials are used in Rezdiffra’s production?
Cell lines, culture media, and purification resins supplied by companies like Wuxi Biologics and Lonza.
4. Who are Rezdiffra’s main competitors?
Biosimilars such as Kanjinti (Pfizer), Ontruzant (Samsung), and Herzuma (Celltrion).
5. Are there any restrictions on Rezdiffra’s supply chain?
Yes, licensing agreements, manufacturing capacity, and regulatory approvals restrict supply expansion and distribution.
References
- Daiichi Sankyo. (2023). Company Reports and Licensing Agreements.
- Fuji Pharma. (2023). Japanese Biosimilars Production Capabilities.
- European Medicines Agency. (2019). Biosimilar Trastuzumab Approvals.
- FDA. (2022). Biosimilar Product Approvals.
- Wuxi Biologics. (2023). Cell Line and Bioprocess Solutions.
